Myeloma Crowd Radio: Ivan Borrello, MD, Johns Hopkins School of Medicine

One of the two projects funded by the Myeloma Crowd Research Initiative is an immunotherapy called MILs (marrow infiltrating lymphocytes). For high risk myeloma patients, their T-cells are taken out, grown up a hundred fold in the presence of their tumor and then given back a post-transplant. Dr. Borrello gives us an update on his open clinical trlal for high risk patients and shares how is also using the MILs with allogeneic transplant and other future combinations (like with checkpoint inhibitors) and in earlier settings. This immunotherapy can be used in almost 100% of patients with fewer side effects than other types of immunotherapy approaches like CAR T cells. 

You can support this project by donating here: The Myeloma Crowd Research Initiative (MCRI)

Special thanks to our Myeloma Crowd Radio episode sponsor, Takeda Oncology.